Purchase this article with an account.
E. Reichel, D.C. Musch, M.W. Johnson, D.J. D'Amico, T.R. Friberg, R. Landis, M.A. Mainster; Glaucoma as a Possible Factor for Vision Loss in the TTT4CNV Clinical Trial . Invest. Ophthalmol. Vis. Sci. 2003;44(13):5043.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: The TTT4CNV Clinical Trial is a study designed to determine if transpupillary thermotherapy (TTT) is effective in preventing further visual loss from occult choroidal neovascularization (CNV) associated with age-related macular degeneration. Methods: A randomized, sham-controlled, multi-centered study. Results: A review of over 280 patients enrolled in the TTT4CNV Clinical Trial revealed that 7 (2.5%) patients were reported to have loss of vision immediately after TTT. Of these 7 patients, 3 (42.9%) had pre-existing glaucoma, whereas the frequency of pre-existing glaucoma among patients receiving TTT who did not experience visual loss was 4.8% (7/147). This significant association [odds ratio, 15.0 (95% CI,2.8,80.4);P=0.006, Fisher's exact test],albeit based on a small number of patients, led the study's Data and Safety Monitoring Committee to advise adding pre-existing glaucoma as an exclusion criterion for further enrollment. Conclusions: Possible reasons why glaucoma could contribute to a higher risk of acute, severe vision loss upon being treated with TTT and considerations for the management of these patients will be discussed.
This PDF is available to Subscribers Only